Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Walmart | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$647.56B | 41.7x | 3.55 | US$80.56 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.7% Upside | Upgrade to Pro+ | |
Kroger | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$40.25B | 18.8x | -1.13 | US$55.78 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.2% Upside | Upgrade to Pro+ | |
Seven & i Co | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$39.94B | 28.2x | -1.32 | US$15.33 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Seven i ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$39.94B | 28.2x | -1.32 | US$14.95 | -4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sysco | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$37.44B | 19.5x | 1.63 | US$76.18 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.4% Upside | Upgrade to Pro+ | |
Fomento Economico Mexicano | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$36.30B | 26.7x | -0.33 | US$104.30 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.2% Upside | Upgrade to Pro+ | |
Tesco PLC | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$32.64B | 21.9x | 0.21 | US$4.78 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tesco PLC | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$32.64B | 21.9x | 0.21 | US$14.45 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -14.7% Downside | Upgrade to Pro+ | |
Koninklijke Ahold NV | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$31.86B | 15.8x | -0.75 | US$34 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Koninklijke Ahold ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$31.86B | 15.8x | -0.75 | US$34.17 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.1% Upside | Upgrade to Pro+ | |
Aeon ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$24.03B | 105.6x | 1.64 | US$28.01 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CP All ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$17.35B | 26.6x | 0.57 | US$16 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Coles Group | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$16.63B | 22.4x | 12.31 | US$11.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
US Foods | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$14.55B | 27.9x | 2.21 | US$59.48 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.1% Upside | Upgrade to Pro+ | |
Caseys | NASDAQ | Consumer Non-Cyclicals | Food & Drug Retailing | US$14.08B | 27.5x | 2.4 | US$379.32 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.3% Upside | Upgrade to Pro+ | |
Jeronimo Martins SGPS SA ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$11.72B | 16.3x | -2.8 | US$37.27 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.5% Upside | Upgrade to Pro+ | |
Performance Food Group Co | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$11.34B | 25.8x | 2.6 | US$72.79 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.5% Upside | Upgrade to Pro+ | |
Carrefour SA PK | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$11.18B | 12.9x | -0.21 | US$3.40 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.1% Upside | Upgrade to Pro+ | |
Albertsons | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$11.03B | 9.8x | -0.75 | US$19.03 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.9% Upside | Upgrade to Pro+ | |
Sendas Distribuidora | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$10.64B | 88.9x | -0.7 | US$7.88 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sprouts Farmers | NASDAQ | Consumer Non-Cyclicals | Food & Drug Retailing | US$10.19B | 31.7x | 0.94 | US$101.78 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.6% Downside | Upgrade to Pro+ | |
Marks and Spencer | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$9.28B | 16x | 1 | US$4.45 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Marks & Spencer Group Plc | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$9.28B | 16x | 1.01 | US$9.40 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -10.4% Downside | Upgrade to Pro+ | |
Shoprite ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$9.16B | 26.1x | 4.07 | US$16.71 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
J Sainsbury PLC | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$8.82B | 48.9x | -1.43 | US$15.34 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -13.6% Downside | Upgrade to Pro+ | |
Raia Drogasil ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$8.24B | 43.5x | 36.53 | US$4.55 | -6.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.4% Upside | Upgrade to Pro+ | |
Walgreens Boots | NASDAQ | Consumer Non-Cyclicals | Food & Drug Retailing | US$7.93B | -1.4x | 0.02 | US$9.20 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.5% Upside | Upgrade to Pro+ | |
Kesko ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$7.88B | 16.7x | -0.72 | US$9.89 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dino Polska ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$7.87B | 21.5x | 2.4 | US$39.78 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Etablissementen Franz Colruyt ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$6.20B | 5.4x | 0.01 | US$13.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |